A Harvard dean and leading epidemiologist, Andrea Baccarelli, whose research was referenced by health officials in the Trump administration to justify limiting Tylenol use among pregnant women due to alleged autism risks, faced scrutiny in a recent lawsuit against the drug’s manufacturer. A federal judge dismissed his conclusions as ‘unreliable.’
Baccarelli, currently the dean of the Harvard T.H. Chan School of Public Health, provided expert testimony in 2023 asserting that prenatal exposure to acetaminophen, the active component of Tylenol, could lead to neurodevelopmental disorders, including autism and ADHD. Notably, a Harvard representative disclosed that Baccarelli received approximately $150,000 for his involvement in the case. This ruling raises critical questions about the validity of expert testimony in pharmaceutical litigation and the implications for regulatory practices surrounding widely used medications.
Open the full market picture for your next decision →
